लोड हो रहा है...
PD-L1 inhibitors in the pipeline: Promise and progress
Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed and have been approved for various cancers. Compa...
में बचाया:
| में प्रकाशित: | Oncoimmunology |
|---|---|
| मुख्य लेखकों: | , , , , , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Taylor & Francis
2017
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5739559/ https://ncbi.nlm.nih.gov/pubmed/29296516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1365209 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|